GlassScriptPhysician profile
Iouri Melnik
NPI 1235113747
$4,980.97
in general payments reported to CMS, 2019-2025
26 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $942 · 2021: $989 · 2022: $370 · 2023: $636 · 2024: $307 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $576.07 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $439.06 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Lilly USA, LLC | $437.96 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $427.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $425.22 | 2019-2020 | |
| Mylan Specialty L.P. | $295.97 | 2021-2023 | Yupelri |
| Amarin Pharma, INC. | $293.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $284.96 | 2019 | |
| Corcept Therapeutics | $281.05 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.69 | 2020-2021 | |
| Glaxosmithkline, LLC. | $232.86 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Bayer Healthcare Pharmaceuticals INC. | $217.15 | 2023-2024 | |
| Amgen INC. | $152.93 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $151.78 | 2019-2025 | |
| Antares Pharma, INC. | $125.51 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $116.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $57.28 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $46.83 | 2024-2025 | Zoryve |
| Radius Health, INC. | $31.54 | 2025 | Tymlos |
| Dexcom, INC. | $28.70 | 2024 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $21.42 | 2025 | Yupelri |
| Cranial Technologies, INC | $18.74 | 2025 | Doc Band |
| Aimmune Therapeutics, INC. | $18.60 | 2025 | Zenpep |
| Horizon Therapeutics Plc | $15.89 | 2022 | |
| Seqirus USA INC | $15.44 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iouri Melnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.